

GO-Dx Corporation (Aust) Ltd
Preliminary Report

1. Company details

Name of entity: GO-Dx Corporation (Aust) Ltd
ACN: 673 839 613
Reporting period: For the period from Incorporation (22 December 2023) to 30 June 2024
Previous period: N/A - The Company was incorporated on 22 December 2023.

2. Results for announcement to the market

					A\$
Revenue from ordinary activities	up	-	%	to	-
Loss from ordinary activities after tax attributable to the owners of GO-Dx Corporation (Aust) Ltd	down	100.00	%	to	(195,329)
Loss for the year attributable to the owners of GO-Dx Corporation (Aust) Ltd	down	100.00	%	to	(195,329)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The loss for the Group after providing for income tax amounted to \$195,329 (2023: N/A).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security (cents)	0.50	N/A

4. Control gained over entities

Name of entity (or group of entities) over which control was gained: 100% of GO-Dx Corporation Ltd. (a company incorporated in Singapore) and its subsidiaries (99% of Go-Dx Philippines Inc., a company incorporated in the Philippines, and 99% of PT GoDx Corp Indonesia, a company incorporation in Indonesia)

Date control was gained: 2 February 2024

Consolidated loss from ordinary activities after tax of the controlled entity (or group of entities) for the current period to the date of gain of control: \$ 80,920

5. Loss of control over entities

Not applicable

GO-Dx Corporation (Aust) Ltd
Preliminary Report

6. Dividends

Current period

There were no dividends paid, recommended or declared during the current financial period.

Previous financial period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable

8. Details of associates and joint venture entities

Not applicable

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

International Financial Reporting Standards were applied by GO-Dx Corporation Ltd. (wholly-owned subsidiary incorporated in Singapore) and its subsidiaries which were incorporated in Indonesia and the Philippines.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements for the period ended 30 June are in the process of being audited and on publication of the audited financial statements later this month, the accounts are expected to include an unmodified audit opinion.

11. Attachments

Details of attachments (if any):

The Preliminary Report of GO-Dx Corporation (Aust) Ltd for the period ended 30 June 2024 is attached.

12. Signed



Bill Pavlovski
Company Secretary
On behalf of the Board of Directors
GO-Dx Corporation (Aust) Ltd
13 September 2024

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Preliminary Report - 30 June 2024

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Consolidated Statement of Profit or Loss and Other Comprehensive Income**For the Period Ended 30 June 2024**

		22 December 2023 - 30 June 2024
	Note	\$
Other income	1	117,688
Finance income	2(a)	34,257
Consulting and professional fees		(232,927)
Depreciation expense	3	(899)
Employee benefits expense (including directors' fees)	3	(92,558)
Finance expenses	2(b)	(570)
Occupancy expenses	3	(5,634)
Office and administration costs		(14,686)
Loss before income tax		(195,329)
Income tax expense		-
Net loss for the period		(195,329)
Other comprehensive income, net of income tax		
Items that will not be reclassified subsequently to profit or loss		-
Items that will be reclassified to profit or loss when specific conditions are met		
Exchange differences on translating foreign controlled entities	12	(51,615)
Other comprehensive loss for the period, net of tax		(51,615)
Total comprehensive loss for the period		(246,944)
Loss attributable to:		
Members of the parent entity		(195,329)
Total comprehensive loss attributable to:		
Members of the parent entity		(246,944)
Earnings per share:		
Basic earnings/(loss) per share (cents)	15	(0.15)
Diluted earnings/(loss) per share (cents)	15	(0.15)

The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Consolidated Statement of Financial Position
As At 30 June 2024

	Note	2024 \$
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	6	673,557
Trade and other receivables	7	5,229
Other assets	8	429,466
TOTAL CURRENT ASSETS		<u>1,108,252</u>
NON-CURRENT ASSETS		
Property, plant and equipment	9	4,141
TOTAL NON-CURRENT ASSETS		<u>4,141</u>
TOTAL ASSETS		<u>1,112,393</u>
LIABILITIES		
CURRENT LIABILITIES		
Trade and other payables	10	308,473
TOTAL CURRENT LIABILITIES		<u>308,473</u>
TOTAL LIABILITIES		<u>308,473</u>
NET ASSETS		<u>803,920</u>
EQUITY		
Issued capital	11	2,225,907
Reserves	12	(1,226,754)
Accumulated losses	13	(195,329)
Non-controlling interest		96
TOTAL EQUITY		<u>803,920</u>

The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Consolidated Statement of Changes in Equity For the Year Ended 30 June 2024

		Ordinary Shares	Accumulated Losses	Foreign Currency Translation Reserve	Common Control Reserve	Non- Controlling Interests	Total
	Note	\$	\$	\$	\$	\$	\$
Balance at 22 December 2023		-	-	-	-	-	-
Loss for the period	13	-	(195,329)	-	-	-	(195,329)
Total other comprehensive income for the year	12	-	-	(51,615)	-	-	(51,615)
Transactions with owners in their capacity as owners							
Contribution of equity, net of transaction costs	11	2,225,907	-	-	-	-	2,225,907
Common control transaction	12	-	-	-	(1,175,139)	96	(1,175,043)
Balance at 30 June 2024		2,225,907	(195,329)	(51,615)	(1,175,139)	96	803,920

The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Consolidated Statement of Cash Flows
For the Period Ended 30 June 2024

		22 December 2023 - 30 June 2024
	Note	\$
CASH FLOWS FROM OPERATING ACTIVITIES:		
Payments to suppliers and employees		(34,661)
Interest received		<u>2,747</u>
Net cash provided by/(used in) operating activities	14	<u>(31,914)</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash acquired via common control transaction		1,052,543
Payment for investments		<u>(4,836)</u>
Net cash provided by/(used in) investing activities		<u>1,047,707</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Payment of transaction costs		<u>(290,824)</u>
Net cash provided by/(used in) financing activities		<u>(290,824)</u>
Effects of exchange rate changes on cash and cash equivalents		<u>(51,412)</u>
Net increase/(decrease) in cash and cash equivalents held		<u>673,557</u>
Cash and cash equivalents at beginning of period		-
Cash and cash equivalents at end of the period	6(a)	<u><u>673,557</u></u>

The accompanying notes form part of these financial statements.

GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

Notes to the Financial Statements For the Period Ended 30 June 2024

1 Other Income

	22 December 2023 - 30 June 2024
	\$
- recoveries	114,657
- other income	3,031
Total other income	117,688

2 Finance Income and Expenses

(a) Finance income

	22 December 2023 - 30 June 2024
	\$
Interest income	2,747
Foreign currency gain on financial assets and liabilities	31,510
Total finance income	34,257

(b) Finance expenses

Bank charges and interest	570
Total finance expenses	570

3 Expenses

The result for the year includes the following specific expenses:

	22 December 2023 - 30 June 2024
	\$
Employee benefits expense (including directors' fees)	92,558
Depreciation expense - computer equipment	899
Rental expense on operating leases:	
- Minimum lease payments	5,634

Notes to the Financial Statements

For the Period Ended 30 June 2024

4 Acquisition of a Subsidiary - Common Control Transaction

On 02 February 2024, the parent Company acquired a 100% interest of GO-Dx Corporation Ltd. (a company incorporated in Singapore) and resulted in GO-Dx Corporation (Aust) Ltd obtaining control of GO-Dx Corporation Ltd..

The following table shows the assets acquired, liabilities assumed and the purchase consideration at the acquisition date.

	Acquiree's carrying amount \$
<i>Purchase consideration:</i>	
- Fully paid ordinary shares	2,340,150
Total purchase consideration	2,340,150
<i>Assets or liabilities acquired:</i>	
Cash	1,052,543
Trade and other receivables	5,341
Plant and equipment	5,133
Other assets	172,954
Trade and other payables	(70,862)
Total net identifiable assets	1,165,109
Less: non-controlling interests	(98)
Identifiable assets acquired and liabilities assumed	1,165,011
Purchase consideration	2,340,150
Less: Identifiable assets acquired	(1,165,011)
Excess of net assets over purchase consideration paid recognised as reserve	1,175,139

Revenue of GO-Dx Corporation Ltd. included in the consolidated revenue of the Group since the acquisition date on 02 February 2024 amounted to \$NIL with a loss of \$80,920.

In determining the accounting treatment to be applied to this acquisition, the Directors gave consideration to the fact that the Company and GO-Dx Corporation Ltd. were controlled by the same group of major shareholders before and after the acquisition. Accordingly, it was determined that the acquisition met the definition of a re-organisation as outlined in AASB 3 *Business Combination*, whereby the variance between the purchase consideration paid and the net assets acquired is recognised in equity on consolidation.

Notes to the Financial Statements

For the Period Ended 30 June 2024

5 Operating Segments

Segment information

Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (Chief Operating Decision Maker) in assessing performance and determining the allocation of resources.

The Group operates in a single segment, being the medical diagnostics and diagnostics technology sectors of the healthcare industry, pioneering development and innovation with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health, and specific cancers. In respect of geographical segments, other than in Singapore, the Group does not conduct material activities outside the Australia geographical area.

Basis of accounting for purposes of reporting by operating segments

(a) Accounting policies adopted

Unless stated below, all amounts reported to the Board of Directors, being the Chief Operating Decision Maker with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

(b) Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that receives the majority of economic value from the asset. Usually, segment assets are clearly identifiable on the basis of their nature and physical location.

(c) Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

Notes to the Financial Statements

For the Period Ended 30 June 2024

5 Operating Segments (continued)

(d) Segment performance

	Australia 22 December 2023 - 30 June 2024 \$	Singapore 22 December 2023 - 30 June 2024 \$	Elimination 22 December 2023 - 30 June 2024 \$	Total 22 December 2023 - 30 June 2024 \$
REVENUE AND OTHER INCOME				
Revenue from external customers	-	-	-	-
Inter-segment revenue	-	-	-	-
Interest revenue	-	2,747	-	2,747
Other income	160	149,038	-	149,198
Total segment revenue and other income	160	151,785	-	151,945
EXPENSES				
Depreciation expense	-	899	-	899
Interest expense	-	570	-	570
Other segment expenses	114,570	231,236	-	345,806
Total segment expenses	114,570	232,705	-	347,275
Segment net loss	(114,410)	(80,920)	-	(195,330)

(e) Segment assets

	Australia 2024 \$	Singapore 2024 \$	Elimination 2024 \$	Total 2024 \$
Segment assets	249,862	1,133,425	(275,731)	1,107,556
<i>Segment asset increases for the period:</i>				
- Capital expenditure	-	4,836	-	4,836
- Acquisitions	2,340,150	-	(2,340,150)	-
Total segment assets	2,590,012	1,138,261	(2,615,881)	1,112,392

(f) Segment liabilities

Segment liabilities	478,514	107,515	(277,555)	308,474
Total segment liabilities	478,514	107,515	(277,555)	308,474

Notes to the Financial Statements

For the Period Ended 30 June 2024

6 Cash and Cash Equivalents

	Note	2024 \$
Cash on hand		1,113
Cash at bank		672,444
Total cash and cash equivalents	6(a)	673,557

(a) Reconciliation of cash

Cash and cash equivalents reported in the consolidated statement of cash flows are reconciled to the equivalent items in the consolidated statement of financial position as follows:

Cash and cash equivalents	6	673,557
Balance as per consolidated statement of cash flows		673,557

7 Trade and Other Receivables

	2024 \$
CURRENT	
Amounts due from a KMP	156
Amounts due from related companies	4,980
Amount due from non-controlling interest	93
Total current trade and other receivables	5,229

8 Other Assets

	2024 \$
CURRENT	
Prepayments	254,408
Deposit	175,058
Total current other assets	429,466

(a) Deposit

The deposit relates to a share subscription in Pathomics Health Pte. Ltd.

Notes to the Financial Statements

For the Period Ended 30 June 2024

9 Property, Plant and Equipment

	2024 \$
Computer equipment	
At cost	6,382
Accumulated depreciation	<u>(2,241)</u>
Total computer equipment	<u>4,141</u>
Total property, plant and equipment	<u><u>4,141</u></u>

(a) Movements in carrying amounts of property, plant and equipment

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current financial period:

	Computer Equipment \$	Total \$
Period ended 30 June 2024		
Balance at the beginning of period	-	-
Additions through common control transaction	5,133	5,133
Depreciation expense	(899)	(899)
Foreign exchange movements	(93)	(93)
Balance at the end of the period	<u>4,141</u>	<u>4,141</u>

10 Trade and Other Payables

	2024 \$
CURRENT	
Trade payables	111,997
Sundry payables and accrued expenses	153,321
Accrued directors' fees	33,600
Amount due to related companies	8,270
Other payables	<u>1,285</u>
Total current trade and other payables	<u><u>308,473</u></u>

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances.

Notes to the Financial Statements

For the Period Ended 30 June 2024

11 Issued Capital

	2024
	\$
161,650,000 fully paid ordinary shares	2,340,152
Less: Capital raising fees	<u>(114,245)</u>
Total issued capital	<u>2,225,907</u>

(a) Ordinary shares

	2024
	No.
At the beginning of the reporting period	-
Shares issued during the period:	
- shares issued on incorporation of Company	2
- issued as consideration for acquisition of GO-Dx Corporation Ltd.	<u>161,649,998</u>
At the end of the reporting period	<u>161,650,000</u>

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote.

The Company does not have authorised capital or par value in respect of its shares.

12 Reserves

	2024
	\$
Foreign currency translation reserve	
Opening balance	-
Exchange differences on translating foreign controlled entities	<u>(51,615)</u>
Closing balance	<u>(51,615)</u>
Common control reserve	
Opening balance	-
Acquisition of GO-Dx Corporation Ltd.	<u>(1,175,139)</u>
Closing balance	<u>(1,175,139)</u>
Total reserves	<u>(1,226,754)</u>

(a) Foreign currency translation reserve

Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income - foreign currency translation reserve. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

(b) Common control reserve

The common control reserve records any difference between the cost of the transaction and the carrying value of the net assets acquired in a transaction between entities under common control.

Notes to the Financial Statements

For the Period Ended 30 June 2024

13 Accumulated Losses

	2024
	\$
Accumulated losses at the beginning of the financial period	-
Net loss for the period	(195,329)
Accumulated losses at end of the financial period	(195,329)

14 Cash Flow Information

Reconciliation of result for the period to cashflows from operating activities

	2024
	\$
Loss for the period	(195,329)
Non-cash flows in profit:	
- depreciation expense	899
Changes in assets and liabilities:	
- (increase)/decrease in other assets	(1,816)
- increase/(decrease) in trade and other payables	164,332
Net cash provided by/(used in) operating activities	(31,914)

15 Earnings Per Share

(a) Reconciliation of earnings to profit or loss from continuing operations

	2024
	\$
Net loss for the period attributable to the owners of the parent entity	(195,329)
Earnings used to calculate basic EPS from continuing operations	(195,329)
Earnings used in the calculation of dilutive EPS from continuing operations	(195,329)

(b) Earnings used to calculate overall earnings per share

Earnings used to calculate overall earnings per share	(195,329)
---	-----------

(c) Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS

	2024
	No.
Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS	126,289,063
Weighted average number of ordinary shares outstanding during the year used in calculating dilutive EPS	126,289,063